Norvasc REDUCES cardiovascular morbidity and mortality in patients with coronary artery disease

January 1999

New evidence suggests that Norvasc REDUCES cardiovascular morbidity and mortality in patients with coronary artery disease.

This new info comes from the PREVENT trial...designed to see whether Norvasc can slow the progression of atherosclerosis.

It suggests that patients on Norvasc have a 31% lower risk of MI...stroke...and hospitalizations or death from heart disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Celebrex (celecoxib), the first COX-2 selective NSAID to hit the market
Cardiology another angiotensin II receptor blocker called Micardis (telmisartan)
Anticoagulants new recommendations to prevent MIs
Anticoagulants ORAL vitamin K (phytonadione, Mephyton) is now recommended to reverse warfarin's anticoagulant effects
Cardiology Norvasc REDUCES cardiovascular morbidity and mortality in patients with coronary artery disease
Infectious Diseases Lymerix, the first vaccine on the market to prevent Lyme disease
Infectious Diseases whether antibiotics are really necessary before dental procedures to prevent endocarditis
vitamin E reduces the severity of tardive dyskinesia
People taking benzodiazepines seem to have more than DOUBLE the risk of traffic accidents
Is echinacea useful for colds?
Glaucoma more emphasis on glaucoma testing and treatment
Glaucoma Five different drug classes are now available for glaucoma
Gastroenterology new guidelines to prevent and treat ulcers caused by NSAIDs
Neurology & Pain Neurontin (gabapentin) for pain
Neurology & Pain new fentanyl lozenge called Actiq
Women's Health Prometrium (micronized progesterone) is now approved for hormone replacement therapy (HRT)
Practice new report on NON-herbal dietary supplements